Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT04101136
Other study ID # 19-03-0272
Secondary ID KET-265/UN2.F1/E
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date September 30, 2019
Est. completion date July 15, 2021

Study information

Verified date January 2020
Source Dr Cipto Mangunkusumo General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Statin administration is supposed to reduce subclinical atherosclerosis by decreasing LDL cholesterol levels, possibly via lipid-independent anti-inflammatory effect. Its pleiotropic properties also adding beneficial effect against CMV infection.

The investigators plan to study atorvastatin in virally- suppressed HIV-infected patients on stable ART with CMV seropositive and statin-naïve to evaluate the subclinical atherosclerosis changes assessed by carotid intima media thickness (CIMT).


Description:

Extended description of the protocol, including more technical information


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 80
Est. completion date July 15, 2021
Est. primary completion date July 15, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 45 Years
Eligibility Inclusion Criteria:

- Ages between 20 to 45 years old

- Using stable ART at least 1 year

- Positive IgG CMV

- Viral load HIV RNA <50 copies / ml

Exclusion Criteria:

- Undergoing hepatitis C DAA therapy

- Decompensated cirrhosis or acute liver failure

- History of coronary artery disease

- Diabetes mellitus

- History of of brain infection, epilepsy, stroke

- History of rhabdomyolysis or myopathy

- Pregnant or breastfeeding

- Severe depression

- Using statin therapy in the past 6 weeks

- History of statin hypersensitivity

- Framingham Risk Score above 10% within LDL =130

- Framingham Risk Score under 10% within LDL =160

- Out of Periodontitis Index (Upper right molars, top series, upper left molars, lower right molars, bottom series, lower left molars)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Atorvastatin - placebo controlled clinical trial
The participants will get the medication supply every month along with the refill of antiretroviral drugs. The drug and placebo tablets will be administered to patients by a staff member who are privy to the treatment. In the end of every month, each participant should return the unused pills every month

Locations

Country Name City State
Indonesia Cipto Mangunkusumo General Hospital Jakarta Center Jakarta

Sponsors (1)

Lead Sponsor Collaborator
Dr Cipto Mangunkusumo General Hospital

Country where clinical trial is conducted

Indonesia, 

References & Publications (1)

Chastain DB, Stover KR, Riche DM. Evidence-based review of statin use in patients with HIV on antiretroviral therapy. J Clin Transl Endocrinol. 2017 Feb 22;8:6-14. doi: 10.1016/j.jcte.2017.01.004. eCollection 2017 Jun. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Carotid intima medial tunica change Numerical changes (in millimeter) between baseline and 48 weeks. Common Carotid Artery (CCA) intima media thickness measured by using B mode imaging system (Affiniti 70 series), equipped with a linear array transducer > 7 MHz with minimal compression (<10:1) and footprint of at least 3 cm. This procedure is operated by certified Cardiologist.
Reference Siomva I. Intima-media thickness: appropriate evaluation and proper measurement, described. ESC. May 2015;15:21.
(1) 0-week visit, (2) 48-week visit
Secondary Flow mediated vasodilatation change Numerical changes (in percentage) between baseline and 48 weeks FMD.
Using a high-resolution ultrasound linear array transducer, longitudinal images of the right brachial artery (mostly 3-15 cm above the elbow) were recorded at the baseline and for 3 minutes after cuff deflation following suprasystolic compression (50 mmHg over the systolic blood pressure) of the right forearm for 5 minutes. This procedure is operated by certified cardiologist.
Reference:
Charakida M, Masi S, Luscher TF, Kastelein JJ, Deanfield JE.Assessment of atherosclerosis: the role of flow-mediated dilatation.Eur Heart J. 2010 Dec;31(23):2854-61
(1) 0-week visit, (2) 48-week visit
Secondary Liver fibrosis change Numerical changes (in KPa) between baseline and 48 week. The measurement of liver stiffness which uses the velocity of shear waves that travel through the liver using the Fibroscan (Echosens) device. This procedure is operated by certified hepatologist. (1) 0-week visit, (2) 48-week visit
Secondary Liver steatosis change Numerical changes (in dB/m) between baseline and 48 weeks. The measurement of steatosis using the Fibroscan (Echosens) equipped with CAP software. dB/m. This procedure is operated by certified hepatologist. (1) 0-week visit, (2) 48-week visit
Secondary Fasting lipid change Numerical changes of fasting lipid profile consist of total cholesterol, LDL-C, HDL-C and triglyceride in mg/dL. Range of fasting is 8 - 10 hours. The test is located in Cipto Mangunkusumo Hospital or Prodia Laboratory Clinic. (1) 0-week visit, (2) 48-week visit
Secondary Neurocognitive function change Mean or median changes of neurocognitive function change. Neurologist will do supervision while subject do the test. The measurement tool is questionnaire named "neurocognitive test". This item will comprising several aspects:
Trail making test
Symbol digit modalities test
Brief visuospatial memory test revised
California verbal learning test II
(1) 0-week visit, (2) 24-week visit, (3) 48-week visit
Secondary Community Periodontal Index (CPI) This Community Periodontal Index takes into consideration 10 teeth in the oral cavity i.e. 17, 16, 11, 26, 27, 37, 36, 31, 46 and 47 and subsequently evaluates the occurrence of gingival bleeding, presence of supra- and subgingival calculus, periodontal pockets with probing depths between 3.5-6.0 mm, as well as clinical attachment loss. This procedure done by dentist.
CPI score:
Score 0: health periodontal conditions
Score 1: gingival bleeding on probing
Score 2: calculus and bleeding
Score 3: periodontal pocket 4-5 mm
Score 4: periodontal pocket =6 mm Only the worst ?nding from the index teeth is recorded per sextant of teeth.
(1) 0-week visit, (2) 48-week visit
Secondary beta 2-microglobulin change The numerical change of beta 2-microglobulin (in pg/mL) between 0-week visit and 48-week visit. This examination located in Indonesian Medical Education and Research Institute (IMERI) laboratory (1) 0-week visit, (2) 48-week visit
Secondary Soluble CD14 change The numerical change of sCD14 (in pg/mL) between 0-week visit and 48-week visit. This examination located in Indonesian Medical Education and Research Institute (IMERI) laboratory (1) 0-week visit, (2) 48-week visit
Secondary ICAM-1 change The numerical change of ICAM-1 (in pg/mL) between 0-week visit and 48-week visit. This examination located in Indonesian Medical Education and Research Institute (IMERI) laboratory (1) 0-week visit, (2) 48-week visit
Secondary High Sensitivity C-Reactive Protein (hsCRP) change The numerical change of hsCRP (in mg/L) between 0-week visit and 48-week visit. This examination located in Indonesian Medical Education and Research Institute (IMERI) laboratory (1) 0-week visit, (2) 48-week visit
Secondary Vascular Cell Adhesion Molecule-1 (V CAM-1) change The numerical change of V CAM-1 (in pg/mL) between 0-week visit and 48-week visit. This examination located in Indonesian Medical Education and Research Institute (IMERI) laboratory (1) 0-week visit, (2) 48-week visit
See also
  Status Clinical Trial Phase
Recruiting NCT06001320 - De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Trans Recip Early Phase 1
Completed NCT01923766 - Cytotoxic T Cells to Prevent Virus Infections Phase 1
Not yet recruiting NCT05969743 - Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host Disease Phase 2
Recruiting NCT01011712 - The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
Recruiting NCT06034925 - Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients Phase 4
Completed NCT04840199 - A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes. Phase 2
Terminated NCT03502161 - Clinical Evaluation of the QuantiFERON CMV Assay
Not yet recruiting NCT06211543 - Letermovir (LMV) Prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients With CMV Seropositive Donors: an Exploratory Study From Spanish GETH/TC Centers
Recruiting NCT04056533 - Prophylaxis of Cytomegalovirus Infection With Adoptive Cell Inmunotherapy Phase 2
Not yet recruiting NCT04280380 - Cytomegalovirus Infection in Critically Ill Patients and Patients Receiving Anticancer Therapy
Active, not recruiting NCT03924219 - CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients
Not yet recruiting NCT06453460 - Prospect Eval of Efficacy of CMV-TCIP Direct Letermovir Prophylax After Allogen Hemato Cell Transpla Phase 2
Completed NCT02694484 - Search Cytomegalovirus in Healthy Volunteers Stools Samples Selected as Potential Donor for Fecal Microbiota Transplant N/A
Recruiting NCT06011486 - Expansion of Virus-Specific Lymphocytes for Cell Therapy Phase 1
Recruiting NCT04017962 - A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection Phase 2
Terminated NCT03570411 - Evaluating the Clinical Utility of the T-SPOT.CMV Assay for the Prediction of CMV Reactivation Among Pediatric Patients Undergoing Hematopoietic Cell Transplant
Enrolling by invitation NCT04392297 - Clinical and Immunological Features of the CMV Infection Atypical Course in Immunocompetent Individuals
Completed NCT00872703 - Does Normal Brain Imaging Predict Normal Neurodevelopmental Outcome in Fetuses With Proven Cytomegalovirus Infection? N/A
Active, not recruiting NCT01945814 - Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL) Phase 1
Recruiting NCT05041426 - Letermovir for CMV Prevention After Lung Transplantation Phase 2